microport® endovascular was listed as 2016 shanghai pudong new area enterprise institution2017-云顶国际

shanghai, china – shanghai pudong new area technology and finance committee recently released the list of enterprise r&d institutions in pudong new area, and microport endovascular (shanghai) co., ltd. ("microport® endovascular") was listed among the 38 r&d institutions.

since 2000, the district government of pudong new area started the verification work of enterprise r&d institutions based on strict assessment standards in terms of the company's business condition, management mechanism, mid- and long-term r&d schedule, proportion of r&d staff, r&d input, as well as r&d intellectual property.

microport® endovascular primarily focuses on r&d, manufacturing, sales and technical support of the interventional medical devices in the treatment of aortic and peripheral vascular diseases. product and technology oriented, microport® endovascular is dedicated to the r&d and innovation of products with independent intellectual property. up to date, microport® endovascular possesses and applied for 111 patents. its project of "development and industrialization of key technologies in minimally invasive treatment of aortic diseases" won the first prize of shanghai science and technology progress award. meanwhile, the company was listed as "2016 shanghai specialized, sophisticated, distinctive, innovative smes," "2016 shanghai science and technology little giant enterprise (for cultivation)," and "2015 shanghai high- and new-technology enterprises."

since microport® endovascular was listed as one of the enterprise r&d institutions in pudong new area, it signifies the recognition of government authority in microport endovascular's r&d abilities, company governance, mid- and long-term strategic goals, and development plans. the president of microport® endovascular zhenghua miao said: "microport® endovascular will continue to receive the developing concept of continuous innovation and enlarge our r&d input in the field of interventional treatment of aortic and peripheral vascular diseases, to provide patients with more high-quality medical devices with independent intellectual property rights."